Knight Therapeutics Non-GAAP EPS of $0.13, revenue of $148.4M
Source: SeekingAlpha
2026-05-07 07:03:01 ET
More on Knight Therapeutics Inc.
- Knight Therapeutics Inc. (GUD:CA) Shareholder/Analyst Call Prepared Remarks Transcript
- Knight Therapeutics Inc. (GUD:CA) Q4 2025 Earnings Call Transcript
- Knight Therapeutics announces approval of additional indication for MINJUVI in Brazil
- Historical earnings data for Knight Therapeutics Inc.
- Financial information for Knight Therapeutics Inc.
Read the full article on Seeking Alpha
For further details see:
Knight Therapeutics Non-GAAP EPS of $0.13, revenue of $148.4M
Knight Therapeutics Inc.
NASDAQ: GUD:CC
GUD:CC Trading
-4.46% G/L:
$5.57 Last:
163,115 Volume:
$5.83 Open:
GUD:CC Latest News
May 28, 2026 07:30:00 am
Knight to Present at the Jefferies 2026 Healthcare Conference in New York City
May 12, 2026 06:30:00 am
Knight to Present at the 2026 RBC Capital Markets Global Healthcare Conference in New York City
